Marc Belsky

Active Aero Charter, Inc. provides air cargo charter management services. Its online CharterNet service lets shipper's list freight for transport so carriers can bid for the business. The company is a subsidiary of Active Aero Group, Inc. Active Aero Charter was founded in 1996 and is headquartered in Belleville, MI.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Active Aero Group, Inc provides air cargo, air charter and delivery services. The firm provides a transportation management system that works across various modes, including air freight, ground, and air charter. The company was founded in 1996 and is headquartered in Belleville, MI.

DataWave Systems, Inc. develops prepaid and stored-value programs and merchandising solutions. It sells prepaid calling cards and point-of-sale activated prepaid cellular personal identification numbers on a wholesale basis to retail operators and other customers. The company was founded in 1994 and is headquartered in Richmond, Canada.

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C.